Tradestie Institutional Equity Comparison Engine

QQEW vs ABCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, QQEW trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABCL at 27.6x Forward P/E and -1550.0% operating margin (-76.3% YoY). In options structure, QQEW sits in UNCLASSIFIED (86th %ile IV; Dealer Gamma Walls on Pro) against ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
QQEW N/M vs ABCL 27.6x Fwd P/E
Growth & Margin Winner ABCL
Op Margin N/A vs -1550.0% ยท YoY N/A vs -76.3%
Momentum & Technical Winner ABCL
1Y +4.1% vs +209.0% ยท 52W Pos 52% vs 69%
Options & Structure Winner ABCL
UNCLASSIFIED (86th %ile IV) vs CONSOLIDATION (25th %ile IV)
QQEW NASDAQ
First Trust NASDAQ-100 Equal Weighted Index Fund
Institutional Equity
$145.79
-2.13% 1D
Market Cap N/A
1M Return -5.73%
1Y Return +4.1%
Forward P/E N/M
Unified AI Score
58.9 / 100 HOLD
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
1M Return -5.21%
1Y Return +208.98%
Forward P/E 27.6x
Unified AI Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QQEW +4.1% ABCL +208.98% Spread: +204.88 pp (ABCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QQEW TTM Op. Margin: N/A ABCL TTM Op. Margin: -1550.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QQEW vs ABCL. Trailing 12-month operating profitability (QQEW N/A vs ABCL -1550.0%) and valuation multiples (QQEW N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QQEW (1) vs ABCL (9)
Institutional Metric QQEW ABCL Criterion Row Winner
Market Capitalization Scale N/A $3.8B Larger Scale ABCL
Trailing P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY) Growth N/A -76.3% Higher Growth ABCL
Operating Margin (TTM) Profitability N/A -1550.0% Higher Margin ABCL
Net Profit Margin Profitability N/A -248.8% Higher Margin ABCL
Return on Equity (ROE) Capital Efficiency N/A -17.3% Higher ROE ABCL
52-Week Range Position Momentum 52% ($122โ€“$167) 69% ($3โ€“$15) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 1.33ฮฒ ยท 34% Vol 2.31ฮฒ ยท 87% Vol Lower Realized Risk QQEW
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 63.3 / 100 (BUY) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QQEW vs ABCL Buy Guide
QQEW UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 86th %ile
IV Regime Extreme (>80th %ile)
Live QQEW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QQEW nor ABCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.